Precision Oncology: A Global Perspective on Implementation and Policy Development.
Embargo End Date
ICR Authors
Authors
Horgan, D
Tanner, M
Aggarwal, C
Thomas, D
Grover, S
Basel-Salmon, L
Dienstmann, R
Tan, TJY
Park, W-Y
Abu Rasheed, HM
Siu, LL
Ma, B
Ortiz-López, R
Van den Bulcke, M
Taucher, SC
Ferris, A
Starling, N
Malapelle, U
Longshore, J
Saldaña, HAB
Subbiah, V
Tanner, M
Aggarwal, C
Thomas, D
Grover, S
Basel-Salmon, L
Dienstmann, R
Tan, TJY
Park, W-Y
Abu Rasheed, HM
Siu, LL
Ma, B
Ortiz-López, R
Van den Bulcke, M
Taucher, SC
Ferris, A
Starling, N
Malapelle, U
Longshore, J
Saldaña, HAB
Subbiah, V
Document Type
Journal Article
Date
2025-01-01
Date Accepted
2024-12-02
Abstract
Despite the acknowledged merits of precision oncology (PO) and its increasing global implementation, its full potential for advancing care and prevention remains unrealized. The benefits are currently accessible to only limited patient segments because of multifaceted barriers. Successful implementation hinges on various factors-scientific complexities not limited to technical, clinical, regulatory, economic, administrative, and health care policy-related challenges. From building infrastructure to the associated costs, including research and development, testing, processing, and trained personnel, a lack of alignment persists. Administrative alignment with regulatory and payor acceptance is crucial. Health care policy must adapt to the ongoing shift from a one-size-fits-all treatment to a personalized approach. Without official endorsement of long-term gains over short-term costs and the health establishment's readiness for innovation, PO prospects, even in prosperous economies, may stagnate. Lower-income countries face exacerbated challenges, intensifying barriers to adoption. Nevertheless, growing awareness and utilization, driven by recognized potential for patients and public health, along with successful examples and advocacy, are progressively influencing policy for a more inclusive and beneficial approach to PO adoption.
Citation
JCO Global Oncology, 2025, 11 (11), pp. e2400416 -
Source Title
JCO Global Oncology
Publisher
LIPPINCOTT WILLIAMS & WILKINS
ISSN
2687-8941
eISSN
2687-8941